Literature DB >> 9006117

In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.

C P Saris1, P J van de Vaart, R C Rietbroek, F A Blommaert.   

Abstract

Two interesting representatives of a new generation of platinum-based cytostatic drugs that are currently being tested in clinical trials are lobaplatin [1,2-diaminomethylcyclobutane platinum(II) lactate] and oxaliplatin [1,2-diaminocyclohexane platinum (II) oxalate]. Since little is known about the DNA adduct formation of these compounds, we studied their formation in DNA in vitro in calf thymus DNA and in cells. The major adducts formed in vitro were the Pt-GG and Pt-AG intrastrand crosslinks. The latter adducts could be detected using a recently developed 32P-postlabelling method. Using both this assay and atomic absorption spectroscopy, it was shown that there is a substantially higher rate of the in vitro adduct formation by cisplatin, compared with lobaplatin and oxaliplatin. Platinum concentrations required to obtain 90% cell kill during a 2 h incubation of A2780 cells were 15 microM for cisplatin and oxaliplatin and 22 microM for lobaplatin. Using an antiserum originally raised against cisplatin-treated DNA, we were also able to detect platinum-DNA adducts induced by lobaplatin and oxaliplatin. Maximal nuclear staining for all three compounds was observed after a 4 h post-incubation period. The nuclear staining level induced by cisplatin was about 10-fold higher than after lobaplatin and oxaliplatin treatment. GG and AG adducts, measured by 32P-postlabelling, also showed maximum levels at about 4 h after treatment. Relative GG peak levels were 4:1:3 for cisplatin, lobaplatin and oxaliplatin, respectively. The ratios of GG over AG intrastrand crosslinks in the A2780 cells were not significantly different for the various compounds. In conclusion, the 32P-postlabelling technique has been shown to be appropriate for adduct analysis, not only for the classical Pt compounds cisplatin and carboplatin but also for novel platinum compounds like lobaplatin and oxaliplatin. Results indicated large differences in reactivity of the latter compounds to DNA in vitro, compared with cisplatin. This difference was smaller in cells, suggesting enhancement of adduct formation by certain cellular mechanisms and/or compounds. From these studies, no conclusions can be drawn with respect to the cytotoxicity of the different Pt-GG and Pt-AG intrastrand crosslinks formed by these compounds.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9006117     DOI: 10.1093/carcin/17.12.2763

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  30 in total

1.  Development and application of a simple assay to quantify cellular adducts of platinum complexes with DNA.

Authors:  C Kloft; C Eickhoff; K Schulze-Forster; H R Maurer; W Schunack; U Jaehde
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.

Authors:  C L King; S Ramachandran; S G Chaney; L Collins; J A Swenberg; K E DeKrafft; W Lin; L Cicurel; M Barbier
Journal:  Cancer Chemother Pharmacol       Date:  2011-10-04       Impact factor: 3.333

3.  Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin.

Authors:  Kriste A Lewis; Kia K Lilly; Evelyn A Reynolds; William P Sullivan; Scott H Kaufmann; William A Cliby
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

4.  Chiral differentiation of DNA adducts formed by enantiomeric analogues of antitumor cisplatin is sequence-dependent.

Authors:  Olivier Delalande; Jaroslav Malina; Viktor Brabec; Jirí Kozelka
Journal:  Biophys J       Date:  2005-04-01       Impact factor: 4.033

Review 5.  Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

Authors:  F Lévi; G Metzger; C Massari; G Milano
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 6.  Oxaliplatin: a review of its use in the management of metastatic colorectal cancer.

Authors:  L R Wiseman; J C Adkins; G L Plosker; K L Goa
Journal:  Drugs Aging       Date:  1999-06       Impact factor: 3.923

7.  Association Between Dose and Duration of Cisplatin Exposure with Cytotoxicity Effect on Nasopharyngeal Carcinoma Stem Cell.

Authors:  Laksmi Kusuma Wardhani; Widodo Ario Kentjono; Achmad Chusnu Romdhoni
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-03-29

8.  Effects of oxaliplatin and 5-fluorouracil on the healing of colon anastomoses.

Authors:  Eren Ersoy; Hakan Akbulut; Gökhan Moray
Journal:  Surg Today       Date:  2009-01-08       Impact factor: 2.549

Review 9.  Unusual DNA binding modes for metal anticancer complexes.

Authors:  Ana M Pizarro; Peter J Sadler
Journal:  Biochimie       Date:  2009-04-01       Impact factor: 4.079

10.  Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus: a comparison of two preoperative radiochemotherapy regimens.

Authors:  K Fakhrian; A D Ordu; B Haller; J Theisen; F Lordick; V Bišof; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2014-04-16       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.